Cerliponase Alfa Observational Study in the US
← catalyst calendarNCT04476862 · readout in 1,473 d
Sponsored by BioMarin Pharmaceutical (industry) · BMRN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
35estimated
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-08-19 | actual | When the study began enrolling |
| Primary completion | 2030-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-07-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Interventions
- Drug: Cerliponase Alfa — also filed as Brineura
- Device: Administration Kit
Primary outcome
what the primary-completion date above is the date OFSafety surveillance of cerliponase alfa
measured 10 years
Permalink · BMRN's whole pipeline · Catalyst calendar · Every registered study · What changed